{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:42:37Z","timestamp":1790404957892,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the UK MRC"},{"name":"the UK Department for International Development"},{"name":"the NIHR Oxford Biomedical Research Centre"},{"DOI":"10.13039\/501100000780","name":"the European Commission","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK Vaccines"},{"name":"Janssen Vaccines"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2017.07.054","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T09:15:38Z","timestamp":1501665338000},"page":"5454-5459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Vaccines against Ebola virus"],"prefix":"10.1016","volume":"36","author":[{"given":"Navin","family":"Venkatraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Silman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro M.","family":"Folegatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.07.054_b0005","unstructured":"WHO. Origins of the 2014 Ebola epidemic 2015. Available from: <http:\/\/who.int\/csr\/disease\/ebola\/one-year-report\/virus-origin\/en\/>."},{"issue":"8011","key":"10.1016\/j.vaccine.2017.07.054_b0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","article-title":"Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire","volume":"1","author":"Johnson","year":"1977","journal-title":"Lancet (London, England)"},{"issue":"8011","key":"10.1016\/j.vaccine.2017.07.054_b0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(77)92002-5","article-title":"Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire","volume":"1","author":"Pattyn","year":"1977","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.054_b0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/JVI.36.2.465-469.1980","article-title":"Virion nucleic acid of Ebola virus","volume":"36","author":"Regnery","year":"1980","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.054_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0168-1702(93)90063-S","article-title":"Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus","volume":"29","author":"Sanchez","year":"1993","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.07.054_b0030","first-page":"1","article-title":"Ebola vaccines in clinical trial: the promising candidates","author":"Wang","year":"2016","journal-title":"Hum Vaccin Immunotherapeut"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","article-title":"Evaluation in nonhuman primates of vaccines against Ebola virus","volume":"8","author":"Geisbert","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"8207","key":"10.1016\/j.vaccine.2017.07.054_b0040","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(80)92352-1","article-title":"Inactivated vaccine for Ebola virus efficacious in guineapig model","volume":"2","author":"Lupton","year":"1980","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/viro.1998.9176","article-title":"DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge","volume":"246","author":"Vanderzanden","year":"1998","journal-title":"Virology"},{"issue":"6812","key":"10.1016\/j.vaccine.2017.07.054_b0050","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.054_b0055","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"issue":"6949","key":"10.1016\/j.vaccine.2017.07.054_b0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.054_b0065","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vacc Immunol: CVI"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.054_b0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"Ledgerwood","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.054_b0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburgvirus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"Sarwar","year":"2015","journal-title":"J Infect Dis"},{"issue":"9977","key":"10.1016\/j.vaccine.2017.07.054_b0080","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.054_b0085","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebola virus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J Virol"},{"issue":"115","key":"10.1016\/j.vaccine.2017.07.054_b0090","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0095","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O'Hara","year":"2012","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.054_b0100","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebola virus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2017.07.054_b0105","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"issue":"261","key":"10.1016\/j.vaccine.2017.07.054_b0110","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.054_b0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"52","key":"10.1016\/j.vaccine.2017.07.054_b0120","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2017.07.054_b0125","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1093\/infdis\/jir298","article-title":"Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany","volume":"204","author":"Gunther","year":"2011","journal-title":"J Infect Dis"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2017.07.054_b0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","article-title":"Clinical development of Ebola vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Therapeut Adv Vacc"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.054_b0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"De Santis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.054_b0140","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.054_b0145","unstructured":"Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, et al. A monovalent chimpanzee adenovirus Ebola vaccine \u2013 preliminary report. New Engl J Med 2015. Available from: <http:\/\/www.nejm.org\/doi\/suppl\/10.1056\/NEJMoa1411627\/suppl_file\/nejmoa1411627_prelim.pdf>."},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2017.07.054_b0155","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"New Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2017.07.054_b0160","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.054_b0165","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.054_b0170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"New Engl J Med"},{"issue":"10068","key":"10.1016\/j.vaccine.2017.07.054_b0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"9996","key":"10.1016\/j.vaccine.2017.07.054_b0180","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2017.07.054_b0185","unstructured":"Venkatraman N, Sridhar S, Wright D, Bowyer G, Powlson J, Rampling T et al. Safety and immunogenicity of the heterologous prime-boost Ebola virus vaccine regimen \u2013 ChAd3-EBO Z followed by MVA-EBO Z in healthy UK adults. In: European Congress of Clinical Microbiology and Infectious Diseases, 11 April, 2016. Amsterdam; 2016. Available from: <https:\/\/www.escmid.org\/escmid_publications\/escmid_elibrary>."},{"issue":"15","key":"10.1016\/j.vaccine.2017.07.054_b0190","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"Jama"},{"issue":"9984","key":"10.1016\/j.vaccine.2017.07.054_b0195","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"10069","key":"10.1016\/j.vaccine.2017.07.054_b0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.054_b0205","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2214-109X(16)30367-9","article-title":"Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"5","author":"Li","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.vaccine.2017.07.054_b0210","unstructured":"Novavax. Novavax Ebola\/Makona glycoprotein (GP) nanoparticle vaccine candidate update: NHP and clinical data; 2015 [Presentation]. Available from: <http:\/\/novavax.com\/download\/files\/presentations\/Novavax_EBOV_GP_Vaccine_2015_07_21_FINAL.pdf>."},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.054_b0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg","year":"1982","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.vaccine.2017.07.054_b0220","unstructured":"CDC. Manual for the surveillance of vaccine-preventable diseases. Atlanta: Centers for Disease Control and Prevention; 2012."},{"issue":"6123","key":"10.1016\/j.vaccine.2017.07.054_b0225","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.1.6123.1317","article-title":"Prevention of secondary cases of meningococcal disease in household contacts by vaccination","volume":"1","author":"Greenwood","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2017.07.054_b0230","first-page":"h3740","article-title":"a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola","volume":"351","author":"The ring vaccination trial","year":"2015","journal-title":"BMJ (Clinical research ed)."},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3201\/eid2201.151410","article-title":"Effectiveness of ring vaccination as control strategy for Ebola virus disease","volume":"22","author":"Kucharski","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.07.054_b0240","doi-asserted-by":"crossref","first-page":"e0005093","DOI":"10.1371\/journal.pntd.0005093","article-title":"Containing Ebola at the source with ring vaccination","volume":"10","author":"Merler","year":"2016","journal-title":"PLoS Neglect Trop Dis"},{"key":"10.1016\/j.vaccine.2017.07.054_b0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2334-10-25","article-title":"Contingency planning for a deliberate release of smallpox in Great Britain\u2013the role of geographical scale and contact structure","volume":"10","author":"House","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0250","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3201\/eid1005.030419","article-title":"Ring vaccination and smallpox control","volume":"10","author":"Kretzschmar","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.054_b0255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2458-4-34","article-title":"Logistics of community smallpox control through contact tracing and ring vaccination: a stochastic network model","volume":"4","author":"Porco","year":"2004","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0260","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.054_b0265","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3201\/eid2010.140430","article-title":"Biomarker correlates of survival in pediatric patients with Ebola virus disease","volume":"20","author":"McElroy","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2017.07.054_b0270","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.054_b0275","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2217\/bmm.14.75","article-title":"Biomarkers for understanding Ebola virus disease","volume":"8","author":"McElroy","year":"2014","journal-title":"Biomarkers Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0280","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.07.054_b0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coviro.2016.01.006","article-title":"Antibody therapeutics for Ebola virus disease","volume":"17","author":"Zeitlin","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.054_b0290","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.054_b0295","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13059-016-1137-3","article-title":"Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus","volume":"18","author":"Liu","year":"2017","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0305","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(16)30243-1","article-title":"Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study","volume":"5","author":"Sissoko","year":"2017","journal-title":"Lancet Global Health"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.054_b0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/ciw793","article-title":"Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child","volume":"64","author":"Sissoko","year":"2017","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"10043","key":"10.1016\/j.vaccine.2017.07.054_b0315","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.054_b0320","doi-asserted-by":"crossref","first-page":"e008859","DOI":"10.1136\/bmjopen-2015-008859","article-title":"Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations","volume":"6","author":"Thorson","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.054_b0325","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","article-title":"An avian cell line designed for production of highly attenuated viruses","volume":"27","author":"Jordan","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.054_b0330","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/S2214-109X(15)00065-0","article-title":"Health-care worker mortality and the legacy of the Ebola epidemic","volume":"3","author":"Evans","year":"2015","journal-title":"Lancet Global Health"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.054_b0335","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"issue":"15","key":"10.1016\/j.vaccine.2017.07.054_b0340","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"Controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"Randomized","year":"2016","journal-title":"New Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:04:05Z","timestamp":1750781045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17309623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":68,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X17309623"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines against Ebola virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}